Summary
AbbVie Inc. reported solid first-quarter 2025 results, with net revenues increasing by 8.4% to $13.3 billion, driven by robust growth in its immunology franchise, particularly Skyrizi and Rinvoq, which saw significant year-over-year increases. Despite the overall revenue growth, the company experienced a 50.6% decline in Humira revenue due to ongoing biosimilar competition, highlighting the strategic shift towards its newer growth drivers. Diluted earnings per share were $0.72, a slight decrease from the prior year's $0.77, impacted by higher interest expenses and a significant increase in the change in fair value of contingent consideration liabilities, which rose to $1.5 billion from $660 million in the prior year. The company continued its strategic investment in pipeline expansion and business development, highlighted by the acquisition of Nimble Therapeutics for oral peptide therapeutics and the finalization of the Cerevel Therapeutics acquisition for neuroscience indications. Cash flow from operations saw a notable decrease to $1.6 billion from $4.0 billion in the prior year, primarily due to working capital timing and litigation-related payments, though the company maintains strong liquidity with significant credit facilities available. AbbVie also continued its commitment to returning capital to shareholders through consistent dividend payments and share repurchases.
Financial Highlights
56 data points| Revenue | $13.34B |
| Cost of Revenue | $4.00B |
| Gross Profit | $9.34B |
| SG&A Expenses | $3.29B |
| Operating Expenses | $9.61B |
| Operating Income | $3.73B |
| Interest Expense | $700.00M |
| Net Income | $1.29B |
| EPS (Basic) | $0.72 |
| EPS (Diluted) | $0.72 |
| Shares Outstanding (Basic) | 1.77B |
| Shares Outstanding (Diluted) | 1.77B |
Key Highlights
- 1Net revenues grew 8.4% to $13.3 billion, driven by strong performance in Skyrizi (+70.5%) and Rinvoq (+57.2%).
- 2Humira revenue declined significantly by 50.6% due to biosimilar competition, underscoring the company's transition to newer growth drivers.
- 3Diluted EPS was $0.72, down from $0.77 in the prior year, impacted by increased interest expense and higher changes in fair value of contingent consideration.
- 4Acquired Nimble Therapeutics for $288 million, focusing on oral peptide therapeutics for conditions like psoriasis.
- 5Completed final valuation of the Cerevel Therapeutics acquisition, strengthening its neuroscience portfolio.
- 6Cash flow from operations decreased to $1.6 billion from $4.0 billion, largely due to working capital timing and litigation payments.
- 7AbbVie declared a quarterly dividend of $1.64 per share and continued its share repurchase program.